Longboard pharmaceuticals reports first quarter 2024 financial results and provides corporate updates

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results. “i am extremely encouraged by the totality of the bexicaserin data generated to date. the recently presented late-breaking data from the pacific study at aan continues to support the potential of bexicaserin.
LBPH Ratings Summary
LBPH Quant Ranking